Co-evolved ligands to ORF8. Could they reduce SARS-COV-2-excesive inflammation? DOI Creative Commons
Melissa Belló-Pérez, Julio Coll

Published: Dec. 19, 2023

ORF8 is an asymmetric-homodimer SARS-COV-2 accessory protein implicated in excesive human inflammation causing numerous deaths. There no approved drug targeting ORF8, nor it known whether any anti-ORF8 drugs could reduce inflammation. Computationally combining ligand co-evolution of parent molecules with affinity-consensus docking, children candidates for docking to cavities were generated. Targeting the homodimer interface highest affinity scaffolds, hundreds grandchildren predicting nanoMolar affinities, unique high specificities and low toxicity risks Although remaining hypothetical without experimental confirmation, this constitute a new methodological attempt search drug-like interfere SARS-COV-2-dependent excessive

Language: Английский

Predominance of the recombinant SARS-CoV-2 lineages XBB in Rio Grande do Sul State, Brazil: a genomic surveillance study and impact on vaccine response DOI Creative Commons

Bruna Candia Piccoli,

Thaís Regina y Castro, Luíza Funck Tessele

et al.

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: March 22, 2024

Abstract Purpose The COVID-19 pandemic has been marked by novel viral variants, posing challenges to global public health. Recombination, a evolution tool, is implicated in SARS-CoV-2's ongoing evolution. The XBB recombinant lineage, known for evading antibody-mediated immunity, exhibits higher transmissibility without increased disease severity. We investigated the prevalence and genomic features of SARS-CoV-2-positive cases Rio Grande do Sul (RS), Brazil. Methods We sequenced 357 samples from epidemiological weeks (EW) 47/2022 17/2023, included 389 publicly available sequences. Clinical data were obtained DATASUS, e-SUS, SIVEP GRIPE (data recording systems Brazilian Ministry Health) Results Of these, 143 classified as 586 other Omicron lineages. BQ.1.1 lineage was most frequent. In March 2023 (EW 10), became dominant, accounting 83·3% cases. 97·7% XBB-infected patients successfully recovered infection, with low mortality rate. Even receiving three vaccine doses previously infected, 59·5% experienced reinfection XBB. However, interval between infection last dose exceeded year, potentially causing antibody decline. addition, we identified 90 mutations RS circulating XBB, spread throughout genome, notably Spike protein region associated immune resistance. Conclusion This study provides insights into dynamics impact variant becoming predominant first time state. Continued surveillance SARS-CoV-2 crucial effective health management.

Language: Английский

Citations

0
Yip1 interacting factor homolog B mediates the unconventional secretion of ORF8 during SARS-CoV-2 infection DOI Creative Commons
Xiaoyuan Lin,

Beibei Fu,

Yan Xiong

et al.

iScience, Journal Year: 2024, Volume and Issue: 28(1), P. 111551 - 111551

Published: Dec. 9, 2024

Language: Английский

Citations

0
Co-evolved ligands to ORF8. Could they reduce SARS-COV-2-excesive inflammation? DOI Creative Commons
Melissa Belló-Pérez, Julio Coll

Published: Dec. 19, 2023

ORF8 is an asymmetric-homodimer SARS-COV-2 accessory protein implicated in excesive human inflammation causing numerous deaths. There no approved drug targeting ORF8, nor it known whether any anti-ORF8 drugs could reduce inflammation. Computationally combining ligand co-evolution of parent molecules with affinity-consensus docking, children candidates for docking to cavities were generated. Targeting the homodimer interface highest affinity scaffolds, hundreds grandchildren predicting nanoMolar affinities, unique high specificities and low toxicity risks Although remaining hypothetical without experimental confirmation, this constitute a new methodological attempt search drug-like interfere SARS-COV-2-dependent excessive

Language: Английский

Citations

0